Novel artful applications of vaccines at the horizon

Davide Montin1 | Giorgio Ottaviano2 | Maria Sangerardi3 | Mayla Sgrulletti4,5 | Loredana Chini4 | Rosa Maria Dellepiane6 | Baldassarre Martire7 | Caterina Rizzo8 | Viviana Moschese4

1Immunology and Rheumatology Unit, Regina Margherita Children Hospital, Turin, Italy
2Molecular and Cellular Immunology Unit, Great Ormond Street Institute of Child Health, University College of London, London, United Kingdom
3Department of Pediatrics and Emergency, Azienda Ospedaliero Universitaria Consorziale Policlinico, Ospedale Pediatrico Giovanni XXIII, Bari, Italy
4Pediatric Immunopathology and Allergology Unit, University of Rome Tor Vergata, Policlinico Tor Vergata, Rome, Italy
5PhD Program in Immunology, Molecular Medicine and Applied Biotechnology, University of Rome Tor Vergata, Rome, Italy
6Pediatric Intermediate Care Unit, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
7Pediatrics and Neonatology Unit, Maternal-Infant Department, Monsignor A.R. Dimiccoli Hospital, Barletta, Italy
8Innovation and Clinical Pathways Unit, Bambino Gesù Children’s Hospital, IRCCS, Rome, Italy

Abstract
Some live vaccines, particularly Bacillus Calmette-Guérin (BCG), oral polio vaccine (OPV), and measles vaccine, can reduce the incidence of all-cause mortality by out-reaching the mere control of specific infections and exerting off-target effects. Aside from the prevention of viral infection, some other vaccines, such as those against flu or rotavirus, could reduce the risk of developing autoimmunity. The nonspecific effects of vaccines are mediated by the innate immune system, mainly through the so-called trained innate immunity. These observations paved the way for developing tolerogenic and trained immunity-based vaccines with substantial implications for more effective use of vaccines and combat vaccine hesitancy.

KEYWORDS
autoimmunity, BCG, diabetes, measles, mRNA vaccines, nonspecific effects, vaccines

Editor: Gian Luigi Marseglia
1 | INTRODUCTION

Vaccines represent a milestone in preventive and social medicine since the 19th century. Apart from specific effects against infectious diseases and their complications, vaccines intriguingly emerge with nonspecific protective effects. Further knowledge of how they work and the availability of novel manufacturing techniques can open new avenues in vaccine policy.

2 | CAN VACCINES HAVE NONSPECIFIC PROTECTIVE EFFECTS?

Off-target effects of vaccines were observed almost a century ago, but only recently, further interest has been raised to impact overall human health. A growing body of literature is suggesting that several live vaccines, remarkably Bacillus Calmette-Guérin (BCG), oral polio vaccine (OPV), measles, and smallpox vaccines, reduce the incidence of all-cause mortality in vaccinated compared to unvaccinated populations outreaching the mere prevention of their target infection. Although most evidence derives from epidemiological observational studies, which are exposed at risk of bias, several randomized controlled trials seem to confirm these data, too. Some pediatric studies showed that revaccination with live vaccines is associated with a marked reduction in mortality and lower hospital admission risk for severe non-targeted infections. Also, maternal antibodies have been shown to enhance a beneficial nonspecific effect on survival in infants who received measles and BCG live vaccines. Furthermore, some studies reported the association of BCG vaccination with a reduced risk of atopy and atopic asthma improvement. As observed in several studies, sex and timing of vaccinations seem to affect nonspecific effects of vaccines.

The recent SARS-CoV-2 pandemic has fostered concern about the heterologous effects of vaccines. Some studies have suggested that confirmed COVID-19 and mortality rates were lower in countries with a BCG vaccination program at birth. However, when different confounding variables were considered, including testing rates, BCG vaccination policy, and COVID-19, spread and mortality rates appear to be uncorrelated.

3 | HOW DO VACCINES PROVIDE NONSPECIFIC EFFECTS?

Although clinical and epidemiological evidence of nonspecific immunomodulation by vaccines has been known for a long time, the immunological mechanisms behind these reports have long remained elusive. An assumption involves the role of heterologous immunity in immunopathology by molecular mimicry. As such, host immune response to a specific pathogen can provide partial protective immunity to unrelated microorganisms. In fact, as well as pathogen-specific T cells cross-react to different peptide-MHC combinations, a similar response might be elicited when T cells are challenged with vaccine antigens. Of note, detrimental effects of triggered cross-reactive immunity can also occur due to excessive activation of Th1 or Th2 compartments that can result in solicited autoimmune or allergic manifestations, respectively. On the other hand, a crucial role of innate immunity for nonspecific protective effects to subsequent unrelated infections after immunization has been recently postulated. How human innate immunity maintains a level of memory to previously encountered pathogens has been only recently investigated. This process has been described as “trained innate immunity” and appears to be related to epigenetic changes occurring in innate immune system cells. In particular, methylation levels of specific lysine residues on the H3 histone tail cause the transition of chromatin from a condensed, transcriptionally inactive form to open, and transcriptionally permissive euchromatin; these epigenetic modifications are detected both in terminally differentiated and in stem cells, are stable over time and can be induced by some pathogen-associated molecular patterns (PAMPs) such as beta-glucan. Proof of principle of this mechanism has been provided by preclinical models, where NOD-SCID mice have been injected with BCG vaccine and showed significant immune protection toward subsequent encounters with Candida albicans, even in the absence of adaptive immunity.

4 | COULD VACCINES PREVENT AUTOIMMUNITY?

Among nonspecific beneficial effects of vaccines, protection against autoimmunity deserves to be mentioned. Several studies have suggested the role of viral infections, especially those caused by RNA viruses (i.e., measles and rotavirus), as triggers of autoimmunity. For instance, in type 1 diabetes (T1D), the interaction between predisposing genes and environmental factors seems to be responsible for the autoimmune attack against β cells. After all, mutations in some genes, such as MDA5 (IFIH1), PTPN2, and TYK2, playing a pivotal role in innate response against RNA viruses, have been associated with T1D development. In this context, it is conceivable that vaccinations, preventing viral infections, could have a protective role against autoimmunity. The potential protective effect of the measles vaccine and Pandemrix flu
vaccine on T1D has been reported. In the same way, a decrease in the incidence of T1D has been recently observed after introducing the routine immunization schedule of the oral Rotavirus vaccine. Rotavirus vaccine has proven safe in individuals at risk of T1D and those at risk of coeliac disease (CD). Moreover, it has been recently reported a higher prevalence of CD in rotavirus-non-vaccinated children than in vaccinated ones, suggesting a role of rotavirus infection, in combination with other genetic and environmental factors, in causing CD.

Despite these limited data, some vaccines seem to be a promising tool to turn down autoimmunity.

5 | ARE THERE NOVEL ARTFUL APPLICATIONS OF VACCINES ON THE HORIZON?

Novel mRNA technology has been recently applied to achieve tolerogenic vaccines. To treat experimental autoimmune encephalomyelitis (EAE), the mouse model for multiple sclerosis, Krienke et al. have developed a vaccine encapsulating an engineered mRNA encoding a myelin antigen in liposomes with a lack of pro-inflammatory activity. The absence of innate immune activation and subsequent production of pro-inflammatory cytokines makes the mRNA transcribed antigen able to induce tolerance instead of sensitization. Even more critical, the mRNA was synthesized, replacing the uridine with 1-methylpseudouridine with consequent inability to engage TLR7. This strategy is highly effective in treating EAE and warrants further applications in the field of organ-specific autoimmunity.

Additional knowledge of those immunologic mechanisms underlying vaccine nonspecific effects can lead to trained immunity-based vaccines. As such, two novel experimental live vaccines, intranasal pertussis, and a new oral Salmonella Typhi vaccine seem to induce an increased immune response to unrelated pathogens.

Although some off-target effects of vaccines have been documented, further issues are to be clarified. For example, optional administration time of live vaccines, the effects of simultaneous administration of live and non-live vaccines, or the interactions with other concomitant health interventions deserve further investigations. Addressing these unsolved questions could bring significant changes to vaccine schedules, including repositioning existing vaccines more effectively.

Last but not least, emphasizing the off-target effects of vaccines could help combat vaccine hesitancy and sustain the undeniable benefits of vaccination.

CONFLICT OF INTEREST

None of the authors reported conflicts of interest.

AUTHOR CONTRIBUTIONS

Davide Montin: Conceptualization (equal); writing-original draft (equal). Giorgio Ottaviano: Writing-review and editing (equal). Maria Sangerardi: Writing-review and editing (equal). Mayla Sgrulletti: Writing-review and editing (equal). Loredana Chini: Writing-review and editing (equal). Rosa Maria Dellepiane: Writing-review and editing (equal), Baldassarre Martire: Writing-review and editing (equal). Caterina Rizzo: Writing-review and editing (equal). Viviana Moschese: Conceptualization (equal); supervision (lead); writing-review and editing (equal).

ORCID

Davide Montin https://orcid.org/0000-0001-8953-2182
Giorgio Ottaviano https://orcid.org/0000-0003-3777-0394
Viviana Moschese https://orcid.org/0000-0001-7650-0632

REFERENCES

1. Benn CS, Fisker AB, Rieckmann A, et al. Vaccinology: time to change the paradigm? Lancet Infect Dis. 2020;20:e274-e283.
2. Higgins JPT, Soares-Weiser K, López-López JA, et al. Association of BCG, DTP, and measles-containing vaccines with childhood mortality: systematic review. BMJ. 2016;355:i5170.
3. de Bree LCJ, Koeken VACM, Joosten LAB, et al. Nonspecific effects of vaccines: current evidence and potential implications. Semin Immunol. 2018;39:35-43.
4. Datta EA, Mewengkang H, Matheos JC, et al. Clinical efficacy and laboratory improvement of bacillus calmette-guerin vaccination on adult atopic asthma. World Allergy Organ J. 2008;1:63-69.
5. Covián C, Retamal-Díaz A, Bueno SM, et al. Could BCG vaccination induce protective trained immunity for SARS-CoV-2? Front Immunol. 2020;11:970.
6. Hensel J, McAndrews KM, McGrail DJ, et al. Protection against SARS-CoV-2 by BCG vaccination is not supported by epidemiological analyses. Sci Rep. 2020;10:18377.
7. van der Heijden CDCC, van der Heijden CDCC, Noz MP, et al. Epigenetics and trained immunity. Antioxid Redox Signal. 2018;29:1023-1040.
8. Moorlag SJCFM, Khan N, Novakovic B, et al. β-Glucan Induces protective trained immunity against mycobacterium tuberculosis infection: a key role for IL-1. Cell Rep. 2020;31:107634.
9. Kleinijenhuis J, Quintin J, Preijers F, et al. Bacille Calmette-Guerin induces NOD2-dependent nonspecific protection from reinfection via epigenetic reprogramming of monocytes. Proc Natl Acad Sci. 2012;109:17537-17542.
10. Morgan E, Halliday SR, Campbell GR, et al. Vaccinations and childhood type 1 diabetes mellitus: a meta-analysis of observational studies. Diabetologia. 2016;59:237-243.
11. Perrett KP, Jachno K, Nolan TM, et al. Association of rotavirus vaccination with the incidence of type 1 diabetes in children. JAMA Pediatr. 2019;173:280-282.
12. Hemming-Harlo M, Lähdeaho M-L, Mäki M, et al. Rotavirus vaccination does not increase type 1 diabetes and may decrease celiac disease in children and adolescents. Pediatr Infect Dis J. 2019;38:539-541.
13. Kemppainen KM, Lynch KF, Liu E, et al. Factors that increase risk of celiac disease autoimmunity after a gastrointestinal infection in early life. Clin Gastroenterol Hepatol. 2017;15:694-702.e5.
14. Krienke C, Kolb L, Díken E, et al. A noninflammatory mRNA vaccine for treatment of experimental autoimmune encephalomyelitis. Science. 2021;371:145-153.

How to cite this article: Montin D, Ottaviano G, Sangerardi M, et al. Novel artful applications of vaccines at the horizon. Pediatr Allergy Immunol. 2022;33(Suppl. 27):83–85. https://doi.org/10.1111/pai.13638